These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 10682234)

  • 21. Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues.
    Dusheiko G
    Liver Int; 2013 Feb; 33 Suppl 1():137-50. PubMed ID: 23286858
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HBsAg loss is not an ideal indicator for discontinuing treatment of HBeAg-negative chronic hepatitis B: a case report.
    Dong PL; Zhang X; Zhao WM; Ding HG
    J Infect Chemother; 2013 Dec; 19(6):1188-92. PubMed ID: 23783395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone.
    Chan HL; Leung NW; Hui AY; Wong VW; Liew CT; Chim AM; Chan FK; Hung LC; Lee YT; Tam JS; Lam CW; Sung JJ
    Ann Intern Med; 2005 Feb; 142(4):240-50. PubMed ID: 15710957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Summaries for patients. Combination therapy for chronic hepatitis B.
    Ann Intern Med; 2005 Feb; 142(4):I30. PubMed ID: 15710953
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
    Furukawa Y; Filiano JJ; Kish SJ
    Mov Disord; 2004 Oct; 19(10):1256-8. PubMed ID: 15389992
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thyrotoxic hypokalemic periodic paralysis as the first manifestation of interferon-alpha-induced Graves disease.
    Cesur M; Gursoy A; Avcioglu U; Erdogan MF; Corapcioglu D; Kamel N
    J Clin Gastroenterol; 2006 Oct; 40(9):864-5. PubMed ID: 17016146
    [No Abstract]   [Full Text] [Related]  

  • 28. Interferon in chronic active hepatitis B: preliminary results.
    Waked I; Amin M; Abd-El Fattah SA; Osman L; Sabbour M
    J Chemother; 1989 Jul; 1(4 Suppl):1086-9. PubMed ID: 16312783
    [No Abstract]   [Full Text] [Related]  

  • 29. Psychosis associated with interferon alfa therapy for chronic hepatitis B.
    Tamam L; Yerdelen D; Ozpoyraz N
    Ann Pharmacother; 2003 Mar; 37(3):384-7. PubMed ID: 12639168
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retreatment with higher dose interferon alpha in children with chronic hepatitis B infection.
    Ozen H; Koçak N; Yüce A; Gürakan F
    Pediatr Infect Dis J; 1999 Aug; 18(8):694-7. PubMed ID: 10462338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A multicenter, randomized, open-label study of the safety and effectiveness of pegylated interferon alpha 2b and interferon alpha 2b in treating HBeAg positive chronic hepatitis B patients].
    Zhao H; Si CW; Wei L; Wan MB; Ying YK; Hou JL; Niu JQ
    Zhonghua Gan Zang Bing Za Zhi; 2006 May; 14(5):323-6. PubMed ID: 16732903
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Partial dopamine agonist therapy of levodopa-induced dyskinesias.
    Baronti F; Mouradian MM; Conant KE; Giuffra M; Brughitta G; Chase TN
    Neurology; 1992 Jun; 42(6):1241-3. PubMed ID: 1351273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Treatment of chronic viral hepatitis].
    Pedersen C; Pedersen CR
    Ugeskr Laeger; 2008 Jun; 170(24):2137-40. PubMed ID: 18565297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dihydropteridine reductase deficiency: levodopa's long-term effectiveness without dyskinesia.
    Sedel F; Ribeiro MJ; Remy P; Blau N; Saudubray JM; Agid Y
    Neurology; 2006 Dec; 67(12):2243-5. PubMed ID: 17190955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M
    Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New concepts in the treatment of Parkinson's disease.
    Ahlskog JE; Wilkinson JM
    Am Fam Physician; 1990 Feb; 41(2):574-84. PubMed ID: 1967895
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
    Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of pegylated interferon/lamivudine therapy on auditory functions in patients with chronic hepatitis B.
    Eser Karlidag G; Karlidag T; Demirdag K; Keles E
    Auris Nasus Larynx; 2011 Jun; 38(3):312-8. PubMed ID: 21216118
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates.
    Johnston TH; Fox SH; Piggott MJ; Savola JM; Brotchie JM
    Mov Disord; 2010 Oct; 25(13):2084-93. PubMed ID: 20824735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unique side effects of interferon.
    Aslam H; Qadeer R; Kashif SM; Rehan M; Afsar S
    J Pak Med Assoc; 2015 Aug; 65(8):895-7. PubMed ID: 26228341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.